KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
Journal of Clinical Oncology2008Vol. 26(3), pp. 374–379
Citations Over TimeTop 1% of 2008 papers
Astrid Lièvre, Jean‐Baptiste Bachet, Valérie Boige, Anne Cayre, Delphine Le Corre, Emmanuel Buc, Marc Ychou, Olivier Bouché, Bruno Landi, Christophe Louvet, Thierry André, Frédéric Bibeau, Marie-Danièle Diébold, Philippe Rougier, Michel Ducreux, Gorana Tomasic, Jean‐François Emile, Frédérique Penault–Llorca, Pierre Laurent‐Puig
Abstract
These results confirm the high prognostic value of KRAS mutations on response to cetuximab and survival in metastatic CRC patients treated with cetuximab.
Related Papers
- → Pharmacokinetic profile of cetuximab (Erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma(2005)80 cited
- → Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer(2011)13 cited
- Evolving role of cetuximab in the treatment of colorectal cancer.(2009)
- → 3518 POSTER Cetuximab with Irinotecan/FA/5-FU as first-line treatment in advanced gastric cancer: Preliminary results of a non-randomized multicenter AIO phase II study(2007)4 cited
- → Abstract C43: Dasatinib resensitizes Kras mutant colorectal tumors to cetuximab(2009)1 cited